https://archive.md/Gq2jB
"In early 2022, around the time the Omicron variant started driving a new surge
in COVID-19 cases, researchers at James DeGregori’s University of Colorado
Anschutz lab noticed something unusual: When lab mice with dormant breast
cancer cells were infected with either influenza or SARS-CoV-2, the animals
were significantly more likely to develop aggressive lung tumors.
What’s true for a mouse isn’t always true for a human. But when the team
examined healthcare databases, they were surprised to find that something
similar appeared to be going on in the human population.
Analysis of records from the U.K. Biobank showed that cancer survivors who
contracted COVID in 2020 — when the virus was new and no vaccine was available
— were significantly more likely to die of recurring cancer than patients who
didn’t get the virus, particularly within the year after their COVID infection.
Analysis of a separate U.S. breast cancer database found that breast cancer
patients in remission who got COVID were significantly more likely to develop
metastatic lung tumors than patients who did not contract the virus.
The University of Colorado researchers couldn’t analyze influenza’s effects as
thoroughly — most flu infections don’t make it into medical charts, as patients
often ride out routine cases at home. They also weren’t able to take into
account whether the severity of a patient’s COVID infection influenced the
likelihood of a cancer recurrence. But COVID’s novelty gave the team the data
it needed to track the effects of viral inflammation on cancer recurrence.
Their results were published last year in the journal
Nature."
Via Violet Blue’s
Threat Model - Ebola - Hantavirus - Covid: June 18, 2026
https://www.patreon.com/violetblue/posts/ebola-hantavirus-161406105
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
